Search clinical trials for: Insulin glulisine (U300)

Total 3998 results

Novo Nordisk A/S

Completed

Effect of Insulin Detemir on Blood Glucose Control in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Canada, Puerto Rico
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Denmark, Spain, Norway, Italy, France, Netherlands
Novo Nordisk A/S

Completed

Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

China
Tonghua Dongbao Pharmaceutical Co.,Ltd

Completed

A Phase III Study of Insulin Aspart Injection to Evaluate the Efficacy and Safety

Diabetes

China
Sanofi

Completed

Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion for Type 1 Diabetes Mellitus Patients

Type 1 Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

A Research Study of How Faster-acting Insulin Aspart Moves Into, Through, and Out of the Body and How it Works in the Body When Given Through an Insulin Pump to People With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Terminated

A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin (iDEAt2)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Mexico, Israel, Taiwan, Malaysia, Hungary, Turkey, Morocco, Germany, South Africa, Portugal, Lebanon, Italy, Brazil, Croatia, Egypt, Spain, Russian Federation, Greece, Argentina, Korea, Republic of, Poland, Serbia
Novo Nordisk A/S

Completed

NovoLet® Surveillance Study on Using Human Insulin System in Indonesia

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Indonesia
Novo Nordisk A/S

Completed

Observational Study on Treatment Satisfaction of Levemir® Versus Protaphane® During "Real-life" Usage in Germany

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Safety and Efficacy of Insulin Aspart in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United Kingdom, Germany, Austria, Denmark, Norway, Sweden, Switzerland, Finland
Novo Nordisk A/S

Completed

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3) (ONWARDS 3)

Diabetes Mellitus, Type 2

United States, Mexico, Puerto Rico, Canada, Denmark, France, Austria, Taiwan, Czechia, Brazil, China, Argentina
HealthPartners Institute
Sanofi; International Diabetes Center at Park Nicollet

Completed

Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia

Hyperglycemia

United States
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Italy, Russian Federation, Slovakia, Spain, Ireland, Germany, Turkey, Bulgaria, Hong Kong, Romania, South Africa
Novo Nordisk A/S

Completed

Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Safety and Efficacy of Insulin Detemir in Combination With OAD in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Poland, Russian Federation, Denmark, Sweden, Macedonia, The Former Yugoslav Republic of, Norway, Croatia, France, Belgium, Slovakia
Novo Nordisk A/S

Completed

Comparing Insulin Aspart With Fast-acting Insulin Human in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4) (ONWARDS 4)

Diabetes Mellitus, Type 2

United States, Japan, Mexico, Russian Federation, Netherlands, Belgium, Italy, India, Romania
Novo Nordisk A/S

Completed

Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes (BEGIN™)

Diabetes | Diabetes Mellitus, Type 1

United States, France, United Kingdom, Russian Federation, Germany, South Africa
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes (BEGIN™)

Diabetes | Diabetes Mellitus, Type 1

United States, Poland, United Kingdom, Belgium, Norway, Germany, Greece
Novo Nordisk A/S

Completed

Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, Puerto Rico, Spain, Russian Federation, Turkey, Austria, India, Korea, Republic of
Imperial College London

Terminated

Management of Type 2 Diabetes After Gastric Bypass Surgery

Diabetes Mellitus, Type 2

United Kingdom
Novo Nordisk A/S

Completed

Examining the Long-term Safety of Insulin Aspart When Used as a Part of the Treatment for Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Russian Federation, Israel, Croatia, Czech Republic, Slovenia
Novo Nordisk A/S

Completed

Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States
Novo Nordisk A/S

Completed

Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes (onset 9)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, Croatia, Italy, Russian Federation, Spain, Canada, Serbia, Slovakia, Germany, Greece, Korea, Republic of, Czechia, Puerto Rico, Bulgaria, Romania, Argentina, Ukraine
Novo Nordisk A/S

Completed

Safety and Efficacy of Insulin Aspart in Children With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
University of Aarhus
Novo Nordisk A/S; The Danish Diabetes Association; The Institute of Experimental...

Completed

Basal Insulins - Pharmacodynamics

Diabetes

Denmark
Novo Nordisk A/S

Terminated

Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin With or Without Metformin in Chinese Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 5)

Diabetes Mellitus, Type 2

United States, Poland, Puerto Rico, Canada, Hungary, Germany, Turkey, Greece
University of Minnesota

Completed

The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients

Cystic Fibrosis

United States
Sanofi

Completed

Health Assessment, Patient Treatment Satisfaction and Quality-of-Life in Insulin-Naive Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

Germany
Novo Nordisk A/S

Completed

Comparison of Antibody Levels in Children and Adolescents After Initiation of Insulin Therapy by Either Insulin Aspart or Soluble Human Insulin

Diabetes | Diabetes Mellitus, Type 1

Sweden
Novo Nordisk A/S

Completed

Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes (Onset® 5)

Diabetes | Diabetes Mellitus, Type 1

United States, Russian Federation, United Kingdom, Canada, France, Netherlands, Belgium, Germany, Slovenia
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic Properties of FIAsp in Japanese Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Observational Study of Type 2 Diabetes Patients Failing on Oral Anti-diabetic Agents Initiated on Levemir® or Insulatard® (EVIDENCE)

Diabetes Mellitus, Type 2 | Diabetes

Romania
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp When Administered as a Bolus in a Continuous Subcutaneous Infusion Regimen in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Sanofi

Completed

Effect of Insulin Glargine in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s)

Diabetes Mellitus, Type 2

United States, Canada
Novo Nordisk A/S

Completed

A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus (BEGIN™)

Diabetes | Diabetes Mellitus, Type 1

Germany, France, United States, Japan, Netherlands, Russian Federation, Bulgaria, United Kingdom, North Macedonia, South Africa, Italy, Finland
Novo Nordisk A/S

Completed

A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes (SWITCH 1)

Diabetes | Diabetes Mellitus, Type 1

United States, Poland, Puerto Rico
Novo Nordisk A/S

Completed

Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population

Diabetes | Diabetes Mellitus, Type 1

United States
Baylor College of Medicine

Completed

The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients (GIH)

Hyperglycemia | Diabetes Mellitus

United States
Eli Lilly and Company

Completed

Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes (IONM)

Diabetes Mellitus, Type 2 | Acute Myocardial Infarction

Canada, Croatia, Czech Republic, Germany, Hungary, India, Israel, Lebanon, Poland, Romania, Russian Federation, Slovakia, Slovenia, South Africa, Spain, Turkey, United Kingdom
Kirsten Nørgaard

Unknown

Fast-Acting Insulin Aspart and Insulin Pump Settings

Type 1 Diabetes

Denmark
Novo Nordisk A/S

Completed

Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine (BOOST®)

Diabetes Mellitus, Type 2 | Diabetes

United States, Malaysia, Germany, Algeria, Turkey
Novo Nordisk A/S

Completed

Pharmacodynamics and Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
University of Palermo

Completed

Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory Variables

Diabetes Mellitus

Italy
University of Aarhus
Novo Nordisk A/S

Completed

A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, BIAsp70, BIAsp50 and Fast-acting Human Insulin

Diabetes Mellitus, Type 1

Denmark

3

Subscribe